Genmab has seen a sharp rerating on the back of recent oncology trial successes, which puts a fresh spotlight on whether the current share price lines up with the cash flows its pipeline may ultimately produce. With the stock now reflecting a very strong run, the key issue is how that market enthusiasm stacks up against an intrinsic value estimate based on its cash generation prospects.
-
Over the past year, Genmab has delivered a 105.9% share price gain, which raises the question of how much future cash flow the market is already factoring in.
-
Positive Phase 3 results for petosemtamab and rinatabart sesutecan may support expectations for higher long term cash inflows, although timing and scale of those potential revenues remain uncertain until regulatory outcomes are clearer.
-
If you'd rather focus on earnings, this one's for you. See why Genmab's 42.9x P/E tells a different valuation story .
The issue now is whether the recent share price level is adequately supported by Genmab's cash flows when measured against an intrinsic value estimate using the Discounted Cash Flow (DCF) approach.
If you want to test the same cash flow question that now surrounds Genmab across a wider set of oncology and biotech stocks, start with 131 healthcare AI stocks .
Is Genmab a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) approach here uses Genmab's projected cash generation to anchor an intrinsic value estimate. Latest twelve month free cash flow sits at about US$838 million, with analysts and modelled estimates indicating higher annual free cash flows over the coming decade rather than a shrinking profile.
On that set of projections, the DCF output indicates an intrinsic value that is substantially above the current traded level of DKK3,788.00 per share. Positive Phase 3 data for petosemtamab in head and neck cancer helps explain why a cash flow based model still supports a higher valuation even after the recent share price strength. You can see the full set of assumptions and resulting intrinsic value estimate in the detailed model. Find out what Genmab could be worth using our Discounted Cash Flow (DCF) estimate .
The Genmab Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Genmab pick up where the valuation puzzle leaves off and explain which assumptions on Genmab's future growth, margins and earnings would need to hold for the shares to be worth materially more or less than today. Rather than relying on a single multiple or model output, each narrative lays out the key building blocks behind its fair value view so you can compare those moving parts with the actual results as they appear on the Community page.
One of the top community narratives on Genmab: 36% overvalued
"The main thing that has to go right is that Genmab converts its broad Phase 3 pipeline in EPKINLY, Rina S and petosemtamab…"
Discover why this Narrative puts Genmab at 36% overvalued .
One last Genmab check that belongs beside the cash flow maths
Price and pipeline only tell part of the story, because who actually steers Genmab and how their rewards line up with your interests can tilt the whole risk return profile. See who runs Genmab and how they are paid .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GMAB.CO .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
